TP53 and melanoma: We thus conducted LY294002 (a PI3K inhibitor) and AKT inhibitor studies in two melanoma cell lines in which AKT was highly phosphorylated: MeWo cells, which have a p53 mutation and VM115 cells, which have functional p53.